Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... that Pierre Noel, M.D., Professor of Medicine, Mayo ... the Company’s Board of Directors. , ... are extremely fortunate to have Dr. Noel, a ... leading healthcare organization, join Entegrion’s Board. His expertise ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Thornton Cleveleys (UK) (PRWEB) March 05, 2015 ... Enhanced implantable polymer have received the CE mark (European) ... within the European Free Trade Association (EFTA) and the ... CE mark has now been granted to implants supplied ... degenerative disc spinal conditions. , Osimplant's Cervical Expandable ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2
... s new server-based file compression software has come out of ... create encrypted self-extracting files in the companys Zip format and ... now open them without needing to install PKWare software themselves. ... which is contained in an executable file. Thats the biggest ...
... a booming export business. Universities are expanding offshore and online ... the South Pacific and the Middle Eastwho are eager for ... is so strong that sale of academic sheepskins is rivaling ... in the land down under should be noted in Wisconsin, ...
... Teresa Esser. Appleton, Wis. The head ... recently to encourage angels to band together. , ,On October ... Foundation, gave a lecture at the Radisson Hotel in ... capitalists invested $18.3 billion in companies of various sizes, but ...
Cached Biology Technology:Encrypted data without the fuss 2Wisconsin can teach the world, and profit by it 2Wisconsin can teach the world, and profit by it 3Susan Preston, entrepreneur, on how to set up angel networks 2Susan Preston, entrepreneur, on how to set up angel networks 3Susan Preston, entrepreneur, on how to set up angel networks 4Susan Preston, entrepreneur, on how to set up angel networks 5
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Failing to see the forest for the trees ... of Wisconsin,s forest ecosystems. Even areas with apparently ... are increasingly fragmented by roads and development, becoming isolated ... tracts, and strip malls, say University of Wisconsin-Madison researchers. ...
... ceremony in this inaugural edition of the BBVA ... on Thursday, June 18, under the presidency of ... Garmendia, and the BBVA Foundation President, Francisco Gonzlez. ... representatives from the international scientific community and high-level ...
... product based on 100% non-allergenic amino-acids specifically designed ... Multiple Food Protein Intolerance Nutricia launches Neocate ... Hepatology and Nutrition (ESPGHAN) Liverpool, UK, ... in advanced medical nutrition, announces the launch of ...
Cached Biology News:Isolated forest patches lose species, diversity 2Isolated forest patches lose species, diversity 3The BBVA Foundation presents its Frontiers of Knowledge Awards 2Nutricia launches Nutra Neocate, weaning product designed for cows’ milk protein allergy 2
SHEEP ANTI FLECAINIDE...
... in refrigerators, freezers, or liquid nitrogen. Conveniently sized to ... color coding to project, user, lab, etc. Holes in ... air circulation. Supplied with 9 x 9 (12.7 mm ... dimensions: 13 x 13 x 5.1 cm H (5 ...
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Biology Products: